• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Richter acquires Finox Holding for $185.2M

Richter acquires Finox Holding for $185.2M

July 1, 2016
CenterWatch Staff

Gedeon Richter has announced the acquisition of Finox Holding, a privately held Swiss biotech company focused on development and commercialization of innovative and cost effective products addressing female fertility. Gedeon Richter, headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe. 

Finox's product, BEMFOLA is a recombinant-human Follicle Stimulating Hormone (r-hFSH), which was developed as a biosimilar to GONAL-f, an established reference product. BEMFOLA was the first biosimilar r-hFSH launched in Europe. It is currently commercialized in the European Union, in Israel, in the Middle East and in Australia. The product gained significant market share since its initial introduction in Q2 2014.

Consequent to this acquisition, Richter will integrate the Finox team focusing on female fertility as part of its growing specialized Women's Healthcare business. Finox's senior management and commercial teams have extensive experience in women's reproductive medicine from leading international pharmaceutical companies.

Finox represents a unique opportunity for Richter to widen its core Women's Healthcare franchise and further emphasizes its commitment to biosimilar business. This acquisition allows Richter to establish its presence in the female fertility therapeutic area—a major growth market.

"Finox represents an important strategic opportunity for Richter in our core therapeutic area and will expand our Women's Healthcare portfolio. I look forward to working with the Finox team to further build on the success that they have made with BEMFOLA, which in turn is expected to provide an opportunity to further strengthen this specialty business segment in most of our key regions and even widen our geographic scope. I am convinced that the acquisition of Finox and the commercialization of BEMFOLA will create increasing value for our investors", said Erik Bogsch, managing director of Gedeon Richter.

"Finox is in a commercial expansion phase in Europe and is growing rapidly. The achievement of the company in launching BEMFOLA in more than 20 countries within 12 months and reaching double digit market share in many of them is unprecedented and I am aware of the investment that this requires. We are extremely pleased to have Richter to commercialize BEMFOLA as their existing portfolio and approach to specialty pharma is highly complementary, also they are considered as one of the leaders in the development and marketing of Women's healthcare products worldwide," said Dr. h.c. Willy Michel, the founder, chairman of the board and majority shareholder of Finox Holding.

The purchase price for the shares in Finox amounts to CHF190 million ($185.2 million).

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing